Alzheimer’s disease, a devastating neurodegenerative disorder, along with other forms of dementia, currently affects an estimated 55 million individuals worldwide. This staggering figure includes approximately 7.2 million cases in the United States alone, reflecting a profound public health crisis. Alarmingly, the global incidence of dementia is growing rapidly, with 10 million new cases reported each year. Projections estimate that by 2030, close to 78 million people will be living with dementia, escalating further to 139 million by 2050. This upward trajectory pressures the scientific community to intensify research efforts aimed at prevention, early detection, and effective therapeutics.
In response to the urgent need for enhanced dementia research, Texas A&M Health, alongside its Division of Research, has established the Dementia & Alzheimer’s Research Initiative (DARI). This innovative program is dedicated to accelerating scientific advancements through targeted seedling grants, recently allocating $1.325 million to support 11 pioneering research projects within Texas A&M University. These endeavors focus explicitly on uncovering novel therapeutic strategies and deepening mechanistic understanding of Alzheimer’s and related dementias.
Among the inaugural recipients of these seedling grants is Karienn Souza, a research assistant professor at the Texas A&M University Naresh K. Vashisht College of Medicine. Souza’s research trajectory emphasizes the intricate relationship between circadian rhythms and cognitive decline, a frontier gaining increasing recognition in neurodegenerative research. Alongside collaborator David Earnest, she has elucidated the detrimental impacts of circadian rhythm dysregulation—particularly observable in shift workers—on the acceleration of cognitive aging.
To unravel the mechanisms underlying this phenomenon, Souza’s team employed an animal model meticulously designed to reflect chronic disruptions in sleep-wake cycles. Their research revealed that such circadian misalignment triggers profound alterations in the brain’s immune landscape, most notably within microglia. These resident immune cells of the central nervous system are essential for maintaining neural homeostasis, participating in debris clearance, synaptic pruning, and modulation of neuroinflammation.
The study’s data indicated that dysregulated circadian rhythms induce microglial activation characterized by morphological and functional transformations. Normally, microglia exhibit a branched, ramified morphology indicative of their surveillance state, continuously monitoring the neural environment. Under inflammatory or pathological conditions, these cells assume an “activated” phenotype, altering their shape and adopting pro-inflammatory behaviors, often described as a stress-primed state. Souza noted the presence of microglia exhibiting extended, irregular branches, distinct from their typical architecture, suggesting impaired function.
This aberrant microglial activation holds profound implications for neurodegenerative disease progression. When microglia become dysfunctional, their efficacy in clearing cellular debris, damaged neurons, and amyloid-beta plaques diminishes. The accumulation of such pathological substrates contributes to synaptic degradation, neuroinflammation, and ultimately the cognitive symptoms characteristic of Alzheimer’s disease. Thus, targeting microglial dysfunction offers a promising therapeutic avenue.
Souza’s current DARI-funded project explores interventions aimed at restoring or preserving microglial function. Central to this approach is extracellular vesicle (EV) therapy pioneered by Ashok Shetty, a distinguished professor of cell biology and genetics at the Vashisht College of Medicine. Shetty’s research has demonstrated the efficacy of EVs—nano-sized, membrane-bound particles derived from stem cells—in modulating immune responses within the brain.
These extracellular vesicles convey bioactive molecules such as proteins, lipids, and nucleic acids that can interact with microglial cells, delivering anti-inflammatory signals. By promoting a homeostatic, non-stress-primed microglial phenotype, EV therapy aims to prevent or reverse inflammatory cascades that contribute to neuronal injury. This novel therapeutic modality exemplifies precision medicine geared toward cellular and molecular restoration rather than broad systemic treatments.
In preclinical studies, administration of EVs has shown encouraging results in mitigating microglial activation and diminishing markers of neuroinflammation. Souza’s project intends to build on these findings by investigating whether EV therapy can effectively counteract the detrimental effects of circadian rhythm disruption on microglial function. The experimental design will assess not only morphological changes in microglia but also functional outcomes related to inflammation and cognitive performance.
The implications of this research extend beyond laboratory models to human populations facing environmental and lifestyle challenges. Societal factors such as erratic work schedules, night shifts, and social jet lag impose circadian stress that may increase Alzheimer’s risk, underscoring the importance of understanding environmental contributors to disease. Souza emphasizes that only a small fraction of Alzheimer’s risk—the estimated 3%—derives from genetic predisposition, making environmental influences an essential focus for prevention strategies.
This environmental paradigm shift has the potential to reshape public health policies and workplace practices by highlighting modifiable risk factors. Identifying and mitigating circadian disruptions could form a cornerstone of dementia prevention, alongside pharmacological interventions such as EV therapy. The integration of basic science with translational research afforded by programs like DARI exemplifies the proactive approach needed to combat the expanding dementia epidemic.
Moreover, the DARI initiative fosters multidisciplinary collaboration, a vital component in tackling the complex pathology of Alzheimer’s disease. The partnership between Souza, an emerging investigator, and Shetty, a leading expert in aging and neuroinflammation, illustrates the synergy that seed funding can cultivate. According to Souza, this collaborative environment accelerates discovery and innovation, potentially yielding breakthroughs with far-reaching clinical impact.
As the scientific community confronts the growing burden of dementia, initiatives like DARI offer hope for earlier diagnosis, improved treatment modalities, and ultimately prevention. By advancing our understanding of how immune system dynamics and circadian biology intersect to influence neurodegeneration, researchers are charting new paths toward alleviating a disease that touches millions of lives worldwide. The pursuit of these goals underscores a shared vision: to transform the future of brain health.
Subject of Research: Alzheimer’s disease, dementia, circadian rhythms, microglial activation, extracellular vesicle therapy
Article Title: The Role of Circadian Rhythm Dysregulation and Microglial Modulation in Alzheimer’s Disease: Insights from Texas A&M’s Dementia & Alzheimer’s Research Initiative
News Publication Date: Not provided
Web References:
– Dementia Statistics: https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
– Alzheimer’s Facts and Figures (USA): https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf
– Texas A&M Dementia & Alzheimer’s Research Initiative: https://health.tamu.edu/dari/index.html
– Circadian Rhythm Dysregulation Study: https://vitalrecord.tamu.edu/shift-work-may-lead-to-accelerated-cognitive-decline-research-suggests/
– Microglia Information: https://www.ataxia.org/scasourceposts/snapshot-what-are-microglia/
– Extracellular Vesicle Therapy Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11536387/
Keywords: Alzheimer’s disease, dementia, circadian rhythm, microglia, neuroinflammation, extracellular vesicle therapy, neurodegeneration, cognitive decline, brain immune system, shift work, Texas A&M Health, Dementia & Alzheimer’s Research Initiative
